BIOMAT Database Logo BIOMAT Database Logo

Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment. 2022

Chaofan Wang, and Jie Li, and Lingzhi Qu, and Xia Tang, and Xiaojuan Song, and Fang Yang, and Xiaojuan Chen, and Qianmeng Lin, and Weibin Lin, and Yang Zhou, and ZhengChao Tu, and Yongheng Chen, and Zhang Zhang, and Xiaoyun Lu
International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China.

MET alterations have been validated as a driven factor in NSCLC and gastric cancers. The c-Met inhibitors, capmatinib, tepotinib, and savolitinib, are only approved for the treatment of NSCLC harboring exon 14 skipping mutant MET. We used a molecular hybridization in conjunction with macrocyclization strategy for structural optimization to obtain a series of 2-(2-(quinolin-6-yl)ethyl)pyridazin-3(2H)-one derivatives as new c-Met inhibitors. One of the macrocyclic compounds, D6808, potently inhibited c-Met kinase and MET-amplified Hs746T gastric cancer cells with IC50 values of 2.9 and 0.7 nM, respectively. It also strongly suppressed Ba/F3-Tpr-Met cells harboring resistance-relevant mutations (F1200L/M1250T/H1094Y/F1200I/L1195V) with IC50 values of 4.2, 3.2, 1.0, 39.0, and 33.4 nM, respectively. Furthermore, D6808 exhibited extraordinary target specificity in a Kinome profiling against 373 wild-type kinases and served as a promising macrocycle-based compound for further anticancer drug development.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D047028 Macrocyclic Compounds Cyclic compounds with a ring size of approximately 1-4 dozen atoms. Macrocycle Compounds,Spherands,Torands,Compounds, Macrocycle,Compounds, Macrocyclic
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D019859 Proto-Oncogene Proteins c-met Cell surface protein-tyrosine kinase receptors for HEPATOCYTE GROWTH FACTOR. They consist of an extracellular alpha chain which is disulfide-linked to the transmembrane beta chain. The cytoplasmic portion contains the catalytic domain and sites critical for the regulation of kinase activity. Mutations in the c-met proto-oncogene are associated with papillary renal carcinoma and other neoplasia. HGF Receptor,Hepatocyte Growth Factor Receptor,c-met Proteins,met Proto-Oncogene Proteins,MET Proto-Oncogene, Receptor Tyrosine Kinase,MET Receptor Tyrosine Kinase,Receptor, HGF,Receptor, Hepatocyte Growth Factor,Receptor, Scatter Factor,Scatter Factor Receptor,c-Met Receptor Tyrosine Kinase,MET Proto Oncogene, Receptor Tyrosine Kinase,Proto Oncogene Proteins c met,Proto-Oncogene Proteins, met,c Met Receptor Tyrosine Kinase,c met Proteins,met Proto Oncogene Proteins

Related Publications

Chaofan Wang, and Jie Li, and Lingzhi Qu, and Xia Tang, and Xiaojuan Song, and Fang Yang, and Xiaojuan Chen, and Qianmeng Lin, and Weibin Lin, and Yang Zhou, and ZhengChao Tu, and Yongheng Chen, and Zhang Zhang, and Xiaoyun Lu
Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.
January 2015, Molecular oncology,
Chaofan Wang, and Jie Li, and Lingzhi Qu, and Xia Tang, and Xiaojuan Song, and Fang Yang, and Xiaojuan Chen, and Qianmeng Lin, and Weibin Lin, and Yang Zhou, and ZhengChao Tu, and Yongheng Chen, and Zhang Zhang, and Xiaoyun Lu
Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment.
March 2024, ACS central science,
Chaofan Wang, and Jie Li, and Lingzhi Qu, and Xia Tang, and Xiaojuan Song, and Fang Yang, and Xiaojuan Chen, and Qianmeng Lin, and Weibin Lin, and Yang Zhou, and ZhengChao Tu, and Yongheng Chen, and Zhang Zhang, and Xiaoyun Lu
Discovery of potent and selective c-Met inhibitors for MET-amplified hepatocellular carcinoma treatment.
January 2024, European journal of medicinal chemistry,
Chaofan Wang, and Jie Li, and Lingzhi Qu, and Xia Tang, and Xiaojuan Song, and Fang Yang, and Xiaojuan Chen, and Qianmeng Lin, and Weibin Lin, and Yang Zhou, and ZhengChao Tu, and Yongheng Chen, and Zhang Zhang, and Xiaoyun Lu
Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer.
December 2023, Journal of medicinal chemistry,
Chaofan Wang, and Jie Li, and Lingzhi Qu, and Xia Tang, and Xiaojuan Song, and Fang Yang, and Xiaojuan Chen, and Qianmeng Lin, and Weibin Lin, and Yang Zhou, and ZhengChao Tu, and Yongheng Chen, and Zhang Zhang, and Xiaoyun Lu
Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models.
April 2018, Molecular cancer therapeutics,
Chaofan Wang, and Jie Li, and Lingzhi Qu, and Xia Tang, and Xiaojuan Song, and Fang Yang, and Xiaojuan Chen, and Qianmeng Lin, and Weibin Lin, and Yang Zhou, and ZhengChao Tu, and Yongheng Chen, and Zhang Zhang, and Xiaoyun Lu
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors.
June 2021, ACS medicinal chemistry letters,
Chaofan Wang, and Jie Li, and Lingzhi Qu, and Xia Tang, and Xiaojuan Song, and Fang Yang, and Xiaojuan Chen, and Qianmeng Lin, and Weibin Lin, and Yang Zhou, and ZhengChao Tu, and Yongheng Chen, and Zhang Zhang, and Xiaoyun Lu
Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
May 2019, ACS medicinal chemistry letters,
Chaofan Wang, and Jie Li, and Lingzhi Qu, and Xia Tang, and Xiaojuan Song, and Fang Yang, and Xiaojuan Chen, and Qianmeng Lin, and Weibin Lin, and Yang Zhou, and ZhengChao Tu, and Yongheng Chen, and Zhang Zhang, and Xiaoyun Lu
Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.
March 2015, Journal of medicinal chemistry,
Chaofan Wang, and Jie Li, and Lingzhi Qu, and Xia Tang, and Xiaojuan Song, and Fang Yang, and Xiaojuan Chen, and Qianmeng Lin, and Weibin Lin, and Yang Zhou, and ZhengChao Tu, and Yongheng Chen, and Zhang Zhang, and Xiaoyun Lu
Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.
August 2016, Journal of medicinal chemistry,
Chaofan Wang, and Jie Li, and Lingzhi Qu, and Xia Tang, and Xiaojuan Song, and Fang Yang, and Xiaojuan Chen, and Qianmeng Lin, and Weibin Lin, and Yang Zhou, and ZhengChao Tu, and Yongheng Chen, and Zhang Zhang, and Xiaoyun Lu
Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.
March 2021, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!